Erich Koller

Title: Erich Koller: Innovator in Antisense Oligonucleotide Technology

Introduction

Erich Koller is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antisense oligonucleotides. His work focuses on innovative solutions for medical challenges, including viral infections.

Latest Patents

One of Erich Koller's key patents is titled "Enhanced oligonucleotides for inhibiting RTEL1 expression." This patent provides antisense oligonucleotides that specifically target the Regulator of telomere elongation helicase 1 (RTEL1). The invention aims to treat and prevent hepatitis B virus (HBV) infections through enhanced antisense oligonucleotides. Additionally, the patent includes pharmaceutical compositions and their applications.

Career Highlights

Throughout his career, Erich Koller has worked with prominent companies in the pharmaceutical industry. He has been associated with Hoffmann-La Roche Inc. and Roche Innovation Center Copenhagen A/S. His experience in these organizations has allowed him to contribute to groundbreaking research and development in biotechnology.

Collaborations

Erich Koller has collaborated with several professionals in his field, including Erik Daa Funder and Natascha Hruschka. These collaborations have further enriched his work and expanded the impact of his inventions.

Conclusion

Erich Koller is a distinguished inventor whose work in antisense oligonucleotide technology has the potential to transform treatments for viral infections. His innovative approach and collaborations highlight his commitment to advancing medical science.